ReviewCurrent oncology reports2017
The Effect of Molecular Diagnostics on the Treatment of Glioma.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Glioma management and outcome in low-middle-income countries: a systematic review.Frontiers in oncology · 2026Pooled it
- Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Molecular subtyping of diffuse gliomas using magnetic resonance imaging: comparison and correlation between radiomics and deep learning.European radiology · 2022Trial
- Mechanisms and functional implications of ZDHHC5 in cellular physiology and disease.Journal of lipid research · 2025Review
- BTK Expression Level Prediction and the High-Grade Glioma Prognosis Using Radiomic Machine Learning Models.Journal of imaging informatics in medicine · 2024Article
- The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.Journal of neuro-oncology · 2024Article
- The E3 ubiquitin ligase RBCK1: Implications in the tumor immune microenvironment and antiangiogenic therapy of glioma.Computational and structural biotechnology journal · 2023Article
- Circular RNA circPTPRF promotes the progression of GBM via sponging miR-1208 to up-regulate YY1.Cancer cell international · 2022Article
- Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.CNS neuroscience & therapeutics · 2022Article
- Article
- Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.Frontiers in genetics · 2022Article
- Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.Molecular and clinical oncology · 2021Article
- Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.The pharmacogenomics journal · 2021Article
- Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-κB signaling.Oncogene · 2021Article
- Expression and prognostic role of E2F transcription factors in high-grade glioma.CNS neuroscience & therapeutics · 2020Article
- Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.BMC cancer · 2020Article
- Radiomics Features Predict CIC Mutation Status in Lower Grade Glioma.Frontiers in oncology · 2020Article
- Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.Medicina (Kaunas, Lithuania) · 2019Review
- The Gut-Brain Axis, Paving the Way to Brain Cancer.Trends in cancer · 2019Review
- A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.Journal of neuropathology and experimental neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes the use of molecular diagnostics in glioma and its effect on the development of novel therapeutics and management decisions. RECENT
findingsGenomic and proteomic profiling of brain tumors has provided significant expansion of our understanding of oncogenesis, characterization, and prognostication of brain tumors. Molecular markers such as MGMT, EGFR, IDH, 1p19q, ATRX, TERT, FGFR-TACC, and BRAF are now being used to classify brain tumors as well as influence management decisions. Several of these markers are also being used as therapeutic targets. We review the use of several molecular diagnostics in gliomas and discuss their impact on drug development and clinical trial design. In the future, molecular characterization based on a specific genomic, proteomic as well as transcriptomes for bioformatics analysis will provide clinicians the ability to rationally select drugs with actionable targets for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.